Group 1 - The core viewpoint of the article highlights that Giant Bio (02367) has seen a significant stock price increase, with a rise of over 8% during trading, currently at 34.4 HKD, with a trading volume of 256 million HKD [1] - Giant Bio recently announced the approval of its "recombinant type I α1 collagen and sodium hyaluronate composite solution" as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness through a combined implant solution [1] - CICC expresses optimism regarding the approval of this product, which is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Group 2 - Looking ahead, CICC believes that the company's research and development strength, brand recognition, and team cohesion remain solid, suggesting that there are opportunities for investment as the cosmetics market recovers and contributions from aesthetic medicine increase [1]
巨子生物盘中涨超8% 全球首个注射用重组胶原蛋白和透明质酸钠复合溶液获批